David A. Siegel 9 Meters Biopharma, Inc. Transaction History

Two Sigma Advisers, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.21 - $0.32 $2,730 - $4,160	13,000 New	13,000 $3,000
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.64 $37,466 - $92,224	-144,100 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.52 - $1.0 $3,484 - $6,700	-6,700 Reduced 4.44%	144,100 $86,000
Q4 2021 Feb 14, 2022	BUY	$0.85 - $1.33 $104,380 - $163,324	122,800 Added 438.57%	150,800 $148,000
Q3 2021 Nov 15, 2021	SELL	$1.03 - $1.41 $1.56 Million - $2.14 Million	-1,514,500 Reduced 98.18%	28,000 $36,000
Q2 2021 Aug 16, 2021	BUY	$1.04 - $1.5 $377,312 - $544,200	362,800 Added 30.75%	1,542,500 $1.7 Million
Q1 2021 May 17, 2021	BUY	$0.84 - $2.16 $931,224 - $2.39 Million	1,108,600 Added 1559.21%	1,179,700 $1.38 Million
Q4 2020 Feb 16, 2021	SELL	$0.65 - $1.11 $14,365 - $24,531	-22,100 Reduced 23.71%	71,100 $61,000
Q3 2020 Nov 16, 2020	BUY	$0.48 - $0.84 $44,736 - $78,288	93,200 New	93,200 $76,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.